Azithromycin in posttransplant bronchiolitis obliterans syndrome.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Verleden receives an annual research grant from GlaxoSmithKline (GSK) Belgium, and is holder of the GlaxoSmithKline Chair in Respiratory Pharmacology at the Katholieke Universiteit Leuven, Leuven, Belgium. The remaining authors have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml ).